Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors
January 06, 2022 07:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results
December 02, 2021 07:30 ET
|
Xilio Therapeutics, Inc.
Anticipate First Patient Dosing in Phase 1/2 Clinical Trial for XTX202, a Tumor-Selective IL-2, in First Quarter of 2022 Advancing Phase 1/2 Clinical Trial for XTX101, a Tumor-Selective Anti-CTLA-4...
Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting
November 12, 2021 07:00 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today...
Xilio Therapeutics Announces Closing of Initial Public Offering
October 26, 2021 16:05 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Xilio) a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today...